Abivax S.A.
- Country
- 🇫🇷France
- Ownership
- -
- Employees
- 61
- Market Cap
- $752.4M
- Introduction
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Safety, PK and PD Study of ABX464 in Untreated HIV Patients
- Conditions
- Human Immunodeficiency Virus Infections
- Interventions
- Other: Placebo
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 70
- Registration Number
- NCT02452242
- Locations
- 🇲🇺
CAP Research Ltd, Curepipe, Mauritius
🇹ðŸ‡Chiang Mai University, Chiang Mai, Thailand
🇹ðŸ‡Siriraj Hospital, Mahidol University, Bangkok, Thailand
Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: ABX203 therapeutic Hepatitis B vaccine treatment arm
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 261
- Registration Number
- NCT02249988
- Locations
- 🇳🇿
Auckland City Hospital, Auckland, New Zealand
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Australia
🇦🇺Royal Prince Alfred Hospital, Camperdown, Australia